MUL1 (F1P7T) Rabbit Monoclonal Antibody #63208
- WB
Product Specifications
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 35 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Due to its central role in mitochondrial quality control, dynamics, and survival pathways, dysregulation of MUL1 has been implicated in a variety of human diseases. For example, in some cancers, such as clear cell renal cell carcinoma and bladder cancer, MUL1 can act as a tumor suppressor by promoting autophagy and inhibiting metastasis (7,8). Conversely, studies have shown that MUL1 may play an oncogenic role in breast or lung carcinoma by ubiquitinating and negatively regulating the tumor suppressors p53 and p73 (9). Polymorphisms in the MUL1 gene have been associated with Parkinson's disease (PD) risk, possibly due to its shared mitophagy target Mitofusin-2 in a pathway parallel to the PD-associated proteins PINK1 and Parkin (10). Inactivation of MUL1 in mouse models prevents diet-induced obesity and metabolic syndrome, suggesting it as a potential therapeutic target for conditions like non-alcoholic fatty liver disease (NAFLD) and insulin resistance (11).
- Li, W. et al. (2008) PLoS One 3, e1487.
- Li, J. et al. (2015) Autophagy 11, 1216-29.
- Peng, J. et al. (2016) Mitochondrion 28, 49-53.
- Lokireddy, S. et al. (2012) Cell Metab 16, 613-24.
- Yun, J. et al. (2014) Elife 3, e01958.
- Cilenti, L. et al. (2022) Front Cell Dev Biol 10, 904728.
- Yuan, Y. et al. (2019) Cancer Sci 110, 3533-3542.
- Wu, J. et al. (2024) Int J Biol Sci 20, 3986-4006.
- Di Gregorio, J. et al. (2023) Int J Mol Sci 24, 17176. doi: 10.3390/ijms242417176.
- Puri, R. et al. (2020) Autophagy 16, 176-178.
- Cilenti, L. et al. (2024) Front Mol Biosci 11, 1397565.
Alternate Names
C1orf166; E3 SUMO-protein ligase MUL1; E3 ubiquitin ligase; E3 ubiquitin-protein ligase MUL1; FLJ12875; GIDE; Growth inhibition and death E3 ligase; MAPL; mitochondria-anchored protein ligase; mitochondrial E3 ubiquitin ligase 1; mitochondrial E3 ubiquitin protein ligase 1; mitochondrial ubiquitin ligase activator of NF-kB; Mitochondrial ubiquitin ligase activator of NFKB 1; Mitochondrial-anchored protein ligase; MUL1; MULAN; Putative NF-kappa-B-activating protein 266; RING finger protein 218; RING-type E3 ubiquitin transferase NFKB 1; RNF218; RP11-401M16.2
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.